StreetAlpha.app
Home › Stocks › ARVN

Arvinas, Inc. (ARVN)

Healthcare
$6.46
▼ −4.15%
LAST CLOSE · NOV 20

Arvinas develops protein degrader medicines that aim to remove disease-causing proteins to treat cancer and neurological diseases. It last closed at $6.46 on Nov 20, down 4.15% on the day. The next earnings report for ARVN is expected around Tue, Feb 23, 2027. For the quarter ended Sep 2026, ARVN reported EPS of -$0.82 on revenue of $500,000, with revenue down 98.8% from a year ago. Over its last 8 reports the stock moved an average of 8.3% the session after earnings. Over the last 12 months ARVN insiders bought $268K of stock on the open market and sold $1.4M, according to SEC Form 4 filings.

AI Auto Pilots
Is ARVN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ARVN.

Key Stats

Last 12 months
Results
Revenue
$275.3M
−11.8% vs a year ago
Net income
−$9.5M
−3.5% margin
EPS (diluted)
−$0.08
Free cash flow
−$159.8M
−58.0% margin
Valuation
Market cap
$423.0M
65.5M shares
P/E
–
No P/E while losing money
Price to sales
1.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$88.0M
At Sep 30
Debt
$400K
At Sep 30
Shareholder equity
$513.8M
Buybacks
$74.1M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $46.7M$46.7MFY2021FY2022: $131.4M$131.4MFY2022FY2023: $78.5M$78.5MFY2023FY2024: $263.4M$263.4MFY2024FY2025: $262.6M$262.6MFY2025

From ARVN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
Feb 23
Estimated date · Time not announced
Reported EPS
-$0.82
Quarter ended Sep 2026
Year ago EPS
-$0.48
Same quarter last year
Revenue
$500,000
−98.8% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.63Dec '24Mar 2025: $1.14Mar '25Jun 2025: -$0.84Jun '25Sep 2025: -$0.48Sep '25Dec 2025: -$0.96Dec '25Mar 2026: -$0.90Mar '26Jun 2026: $2.58Jun '26Sep 2026: -$0.82Sep '26Latest -$0.82
Revenue by quarter
Dec 2024: $59.2MDec '24Mar 2025: $188.8MMar '25Jun 2025: $22.4MJun '25Sep 2025: $41.9MSep '25Dec 2025: $9.5MDec '25Mar 2026: $15.6MMar '26Jun 2026: $249.7MJun '26Sep 2026: $500,000Sep '26Latest $500,000
How ARVN moved after its last 8 reports
Average move the session after a report ±8.3%
Nov 3, 2026Time not announced−5.7%
Aug 4, 2026Time not announced+11.7%
May 12, 2026Time not announced−0.9%
Feb 24, 2026Time not announced+0.6%
Nov 5, 2025Time not announced+0.3%
Aug 6, 2025Time not announced−15.5%
May 1, 2025Time not announced−24.8%
Feb 11, 2025Time not announced−6.8%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ARVNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ARVN
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ARVN

Technical Analysis

ARVN · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 9% below its 20 day and 15% below its 50 day average. It is 43% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 37), near oversold. The nearest support is the 52 week low at $6.33, and the nearest resistance the Pivot at $6.58.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 6.2%/day
Key levels
$14.5152 week high+124.6%
$9.23200 day average+42.9%
$8.06100 day average+24.8%
$7.4050 day average+14.6%
$7.0520 day average+9.1%
$6.96Swing high (Nov 11)+7.7%
$6.74Pivot R1+4.3%
$6.58Pivot+1.9%
$6.46Last close
$6.3352 week low−2.0%
$6.33Swing low (Nov 9)−2.0%
$6.29Pivot S1−2.6%
Indicators
RSI (14)36.66Weak, oversold below 30Neutral
MACD-0.24Below its signal lineBearish
Stochastic19.8Near the bottom of its rangeOversold
ADX (14)25.8Trending down
Williams %R-90.7Oversold below −80, overbought above −20Oversold
CCI (20)-82.5Oversold below −100, overbought above 100Neutral
Rate of change+0.8%Change over 10 sessionsBullish
ATR (14)$0.40Typical daily range, 6.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ARVN

What happened before

See how ARVN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ARVN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ARVN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ARVNHow many large options trades hit ARVN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

ARVN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲107 buying vs 82 selling
  • ▲Held by funds +5.6 pts
  • ▼Funds holding -3
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding198201−1.5%
In funds' top 1012−50.0%
Held by funds91.5%85.9%+5.6 pts
New / increased24 / 8332 / 79−3.6%
Reduced / sold out54 / 2852 / 39−9.9%
Put/call ratio1.591.35+17.6%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ARVN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ARVN Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$268K1 buy · 1 insider
Sold$1.4M19 sales · 6 insiders
5% of the selling was under pre-arranged trading plans.
2026-02 sold $829K2026-03 bought $268K2026-03 sold $71K2026-05 sold $452K2026-06 sold $66K2026-11 sold $1KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 9David K LoomisVP, Chief Accounting OfficerSale plan232$6.36$1K
Jun 24Andrew SaikCFOSale plan5,696$8.16$46K
Jun 17Angela M CacaceChief Scientific OfficerSale plan2,576$7.59$20K
May 21Randy TeelPresident and CEOSale2,209$9.04$20K
May 11Randy TeelPresident and CEOSale9,657$9.94$96K
May 11Noah BerkowitzChief Medical OfficerSale11,108$9.94$110K
Every insider buy and sale for ARVN over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ARVN insider trades →

From SEC Form 4 filings by ARVN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARVN is in one of them and how their past ARVN trades turned out.

ARVN in the AI portfolios
Loading…

ARVN News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ARVN in an article yet. Here's the latest on the wider market.

ARVN in the news

About Arvinas

Arvinas is a biotechnology company based in New Haven, Connecticut. It develops medicines that use targeted protein degradation, a method that removes disease-causing proteins from cells by using the body's own protein disposal system. Its drug candidates focus mainly on cancer and neurological diseases such as Parkinson's disease, and several are in clinical trials with patients. The company also works with larger drug makers, including Pfizer and Genentech, on early-stage research.

Headquarters
New Haven, CT
Founded
2013